In a statement issued by Hikma Pharmaceuticals to Nasdaq Dubai, the Company announced receiving a warning letter from the U.S. Food and Drug Administration (FDA) on October 23, 2014 regarding environmental monitoring and inspection of its Portugal-based manufacturing plant in March 2014. The firm will try to resolve all raised issues with the FDA, Hikma added.


Meanwhile, the Company does not anticipate either financial effect on its FY2014 guidance, or impact on distributing or manufacturing products at its Portugal facility.